Expand IVVD Menu
IVVD MENU

IVVD Latest Press Releases

-- September 8, 2026 --

Invivyd to Participate in Upcoming September Investor Conferences Globe Newswire 7:01 AM

-- September 3, 2026 --

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:01 AM

-- September 1, 2026 --

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY Globe Newswire 7:01 AM

-- August 13, 2026 --

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 4:05 PM

-- August 4, 2026 --

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:01 AM

-- July 6, 2026 --

Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA and Provides an Update on Next Steps with the U.S. FDA Globe Newswire 7:01 AM

-- July 2, 2026 --

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:01 AM

-- June 29, 2026 --

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer Globe Newswire 7:00 AM

-- June 16, 2026 --

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine Globe Newswire 7:01 AM

-- June 9, 2026 --

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration Globe Newswire 7:01 AM

-- June 3, 2026 --

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:01 AM

-- June 1, 2026 --

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID Globe Newswire 7:01 AM

-- May 27, 2026 --

Invivyd to Participate in Upcoming Investor Events Globe Newswire 7:01 AM

-- May 14, 2026 --

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 7:01 AM

-- May 11, 2026 --

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination Globe Newswire 7:01 AM

-- May 7, 2026 --

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 Globe Newswire 7:01 AM

-- May 5, 2026 --

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:01 AM

-- April 20, 2026 --

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit Globe Newswire 7:01 AM

-- April 9, 2026 --

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles Globe Newswire 7:01 AM
Market Data Delayed 15 Minutes